PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392121
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392121
The Global Myeloproliferative Neoplasms Treatment Market is estimated to be valued at US$ 9.4 Billion in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 9.4 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 3.90% | 2030 Value Projection: | US$ 12.28 Bn |
Myeloproliferative neoplasms are a group of rare disorders of the bone marrow that cause an increase in the number of blood cells. The symptoms associated with Myeloproliferative Neoplasms include frequent headaches, tiredness, bruising or unusual bleeding, problem with eyes - such as blurred vision, ringing in the ears, getting more infectious than usual. Moreover, the diagnosis involves blood test to diagnose myeloproliferative neoplasms, the blood tests show the number of blood cells, and can look for genetic mutations. Also, there are other test which done like a bone marrow test, an ultrasound of abdomen.
Different myeloproliferative disorders affect different blood cells that form in the bone marrow. The bone marrow is the soft inner part of bones that makes the blood cells. There are number of different types of myeloproliferative disorders exist, which are;
The key players in the myeloproliferative neoplasm treatment industry are focusing on research and development to develop innovative treatment for myeloproliferative neoplasm. Thus, an increase in research and developement activities in the market is expected to drive the global myeloproliferative neoplasms treatement market growth over the forecast period. For instance, on February 23, 2023, PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that the first patient is now being dosed in a phase 2b clinical study evaluating ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia (ET). BESREMi (ropeginterferon alfa-2b-njft) is innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks (or every four weeks with hematological stability for at least one year), allowing flexible dosing that helps meet the individual needs of patients.